NCT02572284 is a Phase 1 clinical trial of Stereotactic Body Radiation Therapy (SBRT) in Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Who is sponsoring NCT02572284?

NCT02572284 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What drugs are being tested in NCT02572284?

Interventions in NCT02572284: Stereotactic Body Radiation Therapy (SBRT), Prostatectomy, Quality of Life Questionnaires.

What condition does NCT02572284 study?

NCT02572284 studies Prostate Cancer.

Is NCT02572284 still recruiting?

NCT02572284 is currently completed. Last updated 19 January 2023.

Last reviewed 2023-01-19 · How we verify

NCT02572284

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

Completed Phase 1 Last updated 19 January 2023

What this trial tests

Phase 1 trial testing Stereotactic Body Radiation Therapy (SBRT) in Prostate Cancer in 7 participants. Completed in 23 October 2019.

Timeline

27 January 2016

Primary endpoint
5 July 2018

23 October 2019

Quick facts

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	27 January 2016
Primary completion	5 July 2018
Estimated completion	23 October 2019
Sites	1 location across United States

Drugs / interventions tested

Stereotactic Body Radiation Therapy (SBRT) — full drug profile →
Prostatectomy
Quality of Life Questionnaires

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the effects, good and/or bad, of different doses of SBRT given before prostatectomy. Depending when participants enter the study, they will be treated with either 5 or 6 gray (Gy) per day of radiation. A Gy is a measure of radiation dose. The standard dose is 10Gy per day when SBRT is the only treatment to the prostate and no surgery is planned. The researchers want to see which dose of radiation will work best with the least amount of side effects. About 4-6 weeks after SBRT, participants will have a prostatectomy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie.
Sargos P, Supiot S, Créhange G, Fromont-Hankard G, et al · · 2021 · cited 2× · PMID 34885179 · DOI 10.3390/cancers13236070
Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer.
Liveringhouse C, Sim A, Yamoah K, Poch M, et al · · 2021 · PMID 34211768 · DOI 10.5603/rpor.a2021.0027

Verify or expand the search:

Other trials of Stereotactic Body Radiation Therapy (SBRT)

Trials testing the same drug.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07346170 — Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases · NA · not yet recruiting
NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting
NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02572284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 19 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02572284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing